| 1 | clearance for the arx® | | | | | | | 6 | 1.11% |
| 2 | the arx® sai spinal | | | | | | | 5 | 0.92% |
| 3 | for the arx® sai | | | | | | | 5 | 0.92% |
| 4 | 510k clearance for the | | | | | | | 5 | 0.92% |
| 5 | fda 510k clearance for | | | | | | | 5 | 0.92% |
| 6 | arx® sai spinal fixation | | | | | | | 4 | 0.74% |
| 7 | sai spinal fixation system | | | | | | | 4 | 0.74% |
| 8 | announces fda 510k clearance | | | | | | | 4 | 0.74% |
| 9 | accelfixxt devices in the | | | | | | | 3 | 0.55% |
| 10 | published article on the | | | | | | | 3 | 0.55% |
| 11 | releases published article on | | | | | | | 3 | 0.55% |
| 12 | spine releases published article | | | | | | | 3 | 0.55% |
| 13 | devices in the united | | | | | | | 3 | 0.55% |
| 14 | secures federal court order | | | | | | | 3 | 0.55% |
| 15 | of accelfixxt devices in | | | | | | | 3 | 0.55% |
| 16 | sale of accelfixxt devices | | | | | | | 3 | 0.55% |
| 17 | life spine announces fda | | | | | | | 3 | 0.55% |
| 18 | spine announces fda 510k | | | | | | | 3 | 0.55% |
| 19 | lordotic interbody implants in | | | | | | | 3 | 0.55% |
| 20 | spine secures federal court | | | | | | | 3 | 0.55% |
| 21 | static lordotic interbody implants | | | | | | | 3 | 0.55% |
| 22 | federal court order permanently | | | | | | | 3 | 0.55% |
| 23 | life spine releases published | | | | | | | 2 | 0.37% |
| 24 | system by life spine | | | | | | | 2 | 0.37% |
| 25 | or sale of accelfixxt | | | | | | | 2 | 0.37% |
| 26 | the website to function | | | | | | | 2 | 0.37% |
| 27 | for the website to | | | | | | | 2 | 0.37% |
| 28 | marketing or sale of | | | | | | | 2 | 0.37% |
| 29 | in the united states | | | | | | | 2 | 0.37% |
| 30 | court order permanently prohibiting | | | | | | | 2 | 0.37% |
| 31 | life spine offers a | | | | | | | 2 | 0.37% |
| 32 | life spine secures federal | | | | | | | 2 | 0.37% |
| 33 | invasive solution for endoscopic | | | | | | | 2 | 0.37% |
| 34 | by life spine offers | | | | | | | 2 | 0.37% |
| 35 | micro invasive solution for | | | | | | | 2 | 0.37% |
| 36 | expandable versus static lordotic | | | | | | | 2 | 0.37% |
| 37 | article on the effect | | | | | | | 2 | 0.37% |
| 38 | on the effect of | | | | | | | 2 | 0.37% |
| 39 | interbody implants in minimally | | | | | | | 2 | 0.37% |
| 40 | effect of expandable versus | | | | | | | 2 | 0.37% |